Clinical trial
A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors
NCT06586957 is registered in ClinicalTrials.gov with NiKang Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors
- Lead sponsor
- NiKang Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 19, 2024
- Completion date
- May 31, 2029
- Enrollment
- 238 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
advanced endometrial carcinoma, advanced gastric carcinoma, advanced ovarian carcinoma, advanced solid tumor, ccne1 amplification, endometrial diseases, endometrial neoplasms, gastric cancer, hormone receptor negative breast carcinoma, human epidermal growth factor 2 negative carcinoma of breast, metastatic endometrial cancer, metastatic endometrial carcinoma, metastatic gastric cancer, metastatic gastric carcinoma, metastatic ovarian carcinoma, metastatic tumor, ovarian cancer, ovarian carcinoma, ovarian neoplasms, platinum-refractory ovarian carcinoma, platinum-resistant ovarian cancer, progesterone-receptor-positive breast cancer, small cell lung cancer, small cell lung carcinoma, solid tumor, solid tumor, adult, triple negative breast cancer, triple negative breast neoplasms